Related Experiment Video
Updated: Jun 1, 2026

Cellular Redox Profiling Using High-content Microscopy
Published on: May 14, 2017
[Lipodystrophy and metabolic disturbances as complications of antiretroviral therapy]
Monika Bociaga-Jasik1, Beata Kieć-Wilk, Anna Kalinowska-Nowak
1Katedra Gastroenterologii, Hepatologii i Chorób Zakaźnych CMUJ, Kraków. monika.bociagajasik@gmail.com
Abstract:
Effective treatment of HIV infection with antiretroviral drugs significantly improve prognosis. Reduction of mortality and life prolongations in patients receiving such therapy have been also connected with the risk of side effects development. Among these complications metabolic disturbances such as lipodystrophy, dyslipidaemia, and insulin resistance which are present according some authors in up to 50% of patients receiving HAART play an important role. In spite of different investigations molecular basis of lipodystrophy development during HAART have not be fully understood, and the latest research revealed a lot of new aspects connected w adipocyte tissue pathophysiology, which were not taken up to know into consideration. In the presented publication the most important information about pathogenesis of lipodystrophy development in HIV infected patients treated with ARV drugs have been presented.
Related Concept Videos
Complications of Diabetes Mellitus
Retrovirus Life Cycles
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Type I Diabetes III: Clinical Manifestations

